tiprankstipranks
Synergy CHC (SNYR)
NASDAQ:SNYR
US Market
Want to see SNYR full AI Analyst Report?

Synergy CHC (SNYR) AI Stock Analysis

101 Followers

Top Page

SNYR

Synergy CHC

(NASDAQ:SNYR)

Select Model
Select Model
Select Model
Underperform 40 (OpenAI - 5.2)
Rating:40Underperform
Price Target:
$0.16
▼(-4.71% Downside)
Action:Downgraded
Date:07/30/26
The score is driven primarily by very weak financial performance—contracting revenue, large losses, negative cash flow, and a highly leveraged balance sheet with negative equity. Technicals reinforce the risk with the stock trading below all major moving averages and elevated volatility. Corporate events further pressure the outlook due to the loss of a major customer and Nasdaq bid-price compliance risk, while valuation signals are limited because earnings are negative and there is no dividend support.
Positive Factors
High Gross Margin
A sustained gross margin near 67% indicates the core distribution business retains strong unit-level economics and pricing power. That structural margin buffer gives the company scope to absorb SG&A reductions or restructure channels and can materially accelerate recovery once fixed costs and customer mix normalize.
Negative Factors
Major Customer Loss
Losing a customer that supplied ~58% of revenue is a structural shock that will materially depress scale, negotiating leverage, and retail shelf presence. Replacing that volume requires multi-channel redeployment or new large contracts, a prolonged process that will pressure revenue, gross purchasing terms, and working capital for months to years.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
A sustained gross margin near 67% indicates the core distribution business retains strong unit-level economics and pricing power. That structural margin buffer gives the company scope to absorb SG&A reductions or restructure channels and can materially accelerate recovery once fixed costs and customer mix normalize.
Read all positive factors

Synergy CHC (SNYR) vs. SPDR S&P 500 ETF (SPY)

Synergy CHC Business Overview & Revenue Model

Company Description
Synergy CHC Corp. operates as a distributor of diverse consumer health, beauty, and lifestyle merchandise across the United States, Canada, and the United Kingdom. The company's brand portfolio features FOCUSfactor, specializing in nutritional sup...
How the Company Makes Money
null...

Synergy CHC Earnings Call Summary

Earnings Call Date:Apr 01, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Neutral
The call presents a mixed picture. Material one-time charges (notably a $6.66M bad debt allowance, inventory and media write-offs, and a ~$2.9M license revenue reversal) produced large GAAP losses and pushed operating expenses and adjusted EBITDA down. Offsetting these negatives, management highlighted meaningful strategic progress: beverage early traction (Q1 2026 > all of 2025), Mexico subsidiary and Costco Mexico entry, expanded Kroger distribution, stronger cash and working capital, and management’s contention that normalized gross margins are healthy. Operational risks remain (Flat Tummy weakness, TV advertising not restarted, and elevated inventory levels), but management frames many of the financial setbacks as one-time items with a path to improved normalized performance. Overall, positives and negatives are balanced.
Positive Updates
Beverage Business Early Momentum
Generated over $600,000 in gross revenue in Q1 2026 (surpassing all of 2025 beverage revenue), implying a ~$2.5M 2026 run rate; millions of RTD and shot cans in stock and new distribution wins including EG of America (Cumberland Farms), Wakefern Foods, and multiple regional distributors.
Negative Updates
Q4 Revenue Decline and License Reversal
Q4 net revenue was $6.07M vs $10.27M year-ago, a 41% decrease; management reversed ~$2.9M of licensing revenue tied to a terminated UAE/Turkey agreement (CFO cited $2.9M reversal), which materially reduced reported revenue. Excluding the reversal, Q4 revenue would have been $8.97M (a 12.7% YOY decrease).
Read all updates
Q4-2025 Updates
Negative
Beverage Business Early Momentum
Generated over $600,000 in gross revenue in Q1 2026 (surpassing all of 2025 beverage revenue), implying a ~$2.5M 2026 run rate; millions of RTD and shot cans in stock and new distribution wins including EG of America (Cumberland Farms), Wakefern Foods, and multiple regional distributors.
Read all positive updates
Company Guidance
Management guided that normalized gross margin should maintain or improve (Q4 adjusted ~68.8%, FY adjusted ~70.3%), expects the Beverage division to accelerate in 2026 after generating >$600k in Q1 gross revenue (implying a ~$2.5M run-rate), with millions of RTD/shot cans in inventory and new distribution push (EG of America/Cumberland Farms, Wakefern, Costco roadshows, anticipated BJ’s), plans to reactivate TV advertising to drive at least a 15% same‑store sales lift for supplements (3 new SKUs shipped to all 1,600 Kroger stores), and said the balance sheet supports execution with $2.6M cash, $3.7M inventory, a $1.78M working‑capital surplus and improved operating cash use ($2.6M vs $4.8M prior year).

Synergy CHC Financial Statement Overview

Summary
Financials are severely weak: TTM revenue declined (-8.8%) and profitability deteriorated sharply with deeply negative net margin (~-41%), negative operating profit, and negative EBITDA. The balance sheet is highly stressed with consistently negative equity and debt (~$27.7M) far exceeding assets (~$6.5M), creating elevated solvency risk. Cash flow remains negative in TTM (operating and free cash flow), with only modest improvement versus 2024.
Income Statement
24
Negative
Balance Sheet
15
Very Negative
Cash Flow
22
Negative
BreakdownMar 2026Mar 2025Dec 2023Dec 2022Dec 2020
Income Statement
Total Revenue30.38M34.83M42.78M38.41M40.23M
Gross Profit20.30M23.64M32.08M12.96M25.55M
EBITDA-6.17M6.47M10.84M-25.81M2.81M
Net Income-12.34M2.12M6.34M-32.63M1.41M
Balance Sheet
Total Assets10.16M16.34M12.24M18.54M12.59M
Cash, Cash Equivalents and Short-Term Investments2.62M687.92K632.53K1.93M1.67M
Total Debt26.81M27.52M27.62M22.83M8.75M
Total Liabilities33.29M32.97M39.55M52.06M16.27M
Stockholders Equity-23.13M-16.63M-27.31M-33.52M-3.68M
Cash Flow
Free Cash Flow-2.59M-4.80M421.73K-8.43M-1.59M
Operating Cash Flow-2.59M-4.80M421.73K-8.43M-1.59M
Investing Cash Flow0.000.000.000.000.00
Financing Cash Flow4.65M4.80M-2.09M8.96M1.95M

Synergy CHC Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.17
Price Trends
50DMA
0.20
Negative
100DMA
0.39
Negative
200DMA
1.12
Negative
Market Momentum
MACD
-0.01
Negative
RSI
34.25
Neutral
STOCH
13.06
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNYR, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.20, and below the 200-day MA of 1.12, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 34.25 is Neutral, neither overbought nor oversold. The STOCH value of 13.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNYR.

Synergy CHC Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$69.30M-3.16-38.27%16.30%-1069.55%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
43
Neutral
$7.92M-0.071545.09%-51.59%-25.99%
40
Underperform
$2.51M-0.1091.30%-17.53%-221.57%
40
Underperform
$2.71M>-0.0141.78%10.16%98.05%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SNYR
Synergy CHC
0.17
-3.68
-95.70%
RDGT
Ridgetech
0.99
-189.51
-99.48%
GEG
Great Elm Group
2.15
0.00
0.00%
WGRX
Wellgistics Health Inc
1.99
-34.91
-94.61%

Synergy CHC Corporate Events

Business Operations and StrategyFinancial Disclosures
Synergy CHC Faces Major Setback as Costco Exits
Negative
Jul 29, 2026
On July 15, 2026, Costco Wholesale Corporation notified Synergy CHC Corp. that it would discontinue carrying the company’s FOCUSfactor products, ending a commercial relationship that spanned more than 16 years. Costco represented about 58% o...
Executive/Board ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
Synergy CHC Shareholders Approve Key Equity Plan Changes
Positive
Jun 29, 2026
On June 29, 2026, Synergy CHC held its 2026 annual stockholders’ meeting, where investors approved an amendment to its 2024 Equity Incentive Plan, raising the pool to 150,000,000 common shares and allowing repricing of outstanding awards, fo...
Delistings and Listing ChangesRegulatory Filings and Compliance
Synergy CHC Receives Nasdaq Minimum Bid Price Notice
Negative
May 18, 2026
On May 15, 2026, Synergy CHC Corp. disclosed that it had received a notice from Nasdaq stating that the company’s common stock had failed to meet the exchange’s $1.00 minimum bid price requirement for 30 consecutive business days, putt...
Business Operations and StrategyPrivate Placements and Financing
Synergy CHC Establishes Equity Line Financing Agreement
Positive
May 11, 2026
On May 8, 2026, Synergy CHC Corp. entered into an equity purchase agreement with Hudson Global Ventures, giving the company the option over 24 months to sell up to $36 million of common stock under an equity line of credit, subject to volume, pric...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2026